Veracyte Inc’s recently made public that its Chief Commercial Officer-CLIA Leite John unloaded Company’s shares for reported $0.14 million on Nov 25 ’25. In the deal valued at $50.00 per share,2,808 shares were sold. As a result of this transaction, Leite John now holds 86,291 shares worth roughly $4.0 million.
Then, JONES EVAN/ FA sold 1,106 shares, generating $55,576 in total proceeds. Upon selling the shares at $50.25, the Director now owns 29,362 shares.
Before that, Evan Jones bought 5,000 shares. Veracyte Inc shares valued at $246,900 were divested by the Director at a price of $49.38 per share.
Canaccord Genuity initiated its Veracyte Inc [VCYT] rating to a Hold in a research note published on October 20, 2025; the price target was $40. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Goldman also remained covering VCYT and has decreased its forecast on December 05, 2024 with a “Neutral” recommendation from previously “Buy” rating. Wolfe Research started covering the stock on November 15, 2024. It rated VCYT as “an Outperform”.
Price Performance Review of VCYT
On Monday, Veracyte Inc [NASDAQ:VCYT] saw its stock fall -2.01% to $46.39. Over the last five days, the stock has gained 5.41%. Veracyte Inc shares have risen nearly 8.29% since the year began. Nevertheless, the stocks have risen 17.15% over the past one year. While a 52-week high of $50.71 was reached on 11/25/25, a 52-week low of $22.61 was recorded on 07/18/25.
Levels Of Support And Resistance For VCYT Stock
The 24-hour chart illustrates a support level at 45.92, which if violated will result in even more drops to 45.46. On the upside, there is a resistance level at 47.02. A further resistance level may holdings at 47.65.
How much short interest is there in Veracyte Inc?
A steep rise in short interest was recorded in Veracyte Inc stocks on 2025-11-14, dropping by -1.27 million shares to a total of 5.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 6.72 million shares. There was a decline of -23.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 16, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $43 price target.
